晚期结直肠癌抗血管生成靶向治疗研究进展(4)
[12]Bennouna J，Sastre J，Arnold D，et al.Continuation of bevacizumab after first progression in metastatic colorectal cancer(ML18147)：a randomised phase 3 trial[J].Lancet Oncol，2013，14(1)：29-37.[13]Masi G，Salvatore L，Boni L，et al.Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer：final results of the ran-domized BEBYP trial[J].Ann Oncol ......
您现在查看是摘要页，全文长 2633 字符。